Thirty-eight patients with hematological malignancies, received T cell-depleted marrow transplants (BMT) and cyclosporine to prevent acute graft-versus-host disease (aGVHD), followed by delayed add-back of donor lymphocytes to prevent leukemia relapse. In 26 patients scheduled for donor T cell add-back of 2 × 10 6 cells/kg on day 30 and 5 × 10 7 cells/kg on day 45 (schedule 1), the overall probability of grade уII aGVHD developing was 31.5%, with a 15.5% probability of aGVHD occurring after T cell add-back. In 12 patients receiving 10 7 donor T cells/kg on day 30 (schedule 2), the probability of grade уII aGVHD was 100%. The incidence of grade III-IV aGVHD was higher in schedule 2 than in schedule 1 (P = 0.02). Of 24 evaluable patients, 10 (46%) developed chronic GVHD which was limited in eight and extensive in two. Current disease-free survival for 18 patients at standard risk for relapse (chronic myeloid leukemia (CML) in chronic or accelerated phase, acute myeloid leukemia in remission) vs 20 patients with more advanced leukemia or multiple myeloma were respectively 72% vs 12% (P Ͻ 0.01) with a 29% vs 69% probability of relapse (P = 0.08). In 12 CML patients surviving more than 3 months, PCR analysis of the BCR/ABL transcript showed that minimal residual disease after T cell add-back was transient except in two patients who developed hematological relapse. Results indicate that the risk of acute GVHD is low following substantial T cell doses, transfused 45 days after transplant, using cyclosporine prophylaxis. Furthermore a graft-versusleukemia effect was conserved. Keywords: chronic myeloid leukemia; hematological malignancies; graft-versus-host disease; graft-versus-leukemia; T cell-depleted BMT; immune recovery Although T cell depletion of the donor marrow can successfully prevent acute graft-versus-host disease (aGVHD) after Correspondence: Dr AJ Barrett, Bone Marrow Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA Received 21 August 1997; accepted 28 October 1997 allogeneic bone marrow transplantation (BMT), the procedure increases the risk of leukemic relapse, graft failure and prolonged immunosuppression following the transplant.
allogeneic bone marrow transplantation (BMT), the procedure increases the risk of leukemic relapse, graft failure and prolonged immunosuppression following the transplant. [1] [2] [3] [4] [5] [6] [7] Attempts to separate GVHD from the graft-versusleukemia (GVL) response have so far met with only partial success. 8, 9 However, new understanding of the mechanisms involved in GVHD and clinical observations suggest that the risk of aGVHD varies with the timing of donor lymphocyte administration to the BMT recipient. In murine MHCmatched and haplotype-mismatched BMT models, Johnson and Truitt 10, 11 showed that delayed infusion of immunocompetent donor spleen cells 21 days after transplantation did not cause severe aGVHD, but nevertheless conferred a GVL effect. Initial attempts in clinical BMT to enhance the GVL effect by giving additional donor lymphocytes in the first week after BMT met with failure because of severe aGVHD. 12 With more delayed T cell add-back, Naparstek and co-workers 13 found a 42-53% risk of aGVHD from T cell doses of 10 5 -10 7 /kg. In contrast, large doses of donor lymphocytes given to treat leukemia relapsing after BMT induced a relatively low incidence of GVHD, despite the absence of cyclosporine prophylaxis. 14, 15 To explore the possibility that add-back of substantial doses of T cells within the first 3 months after BMT in combination with cyclosporine could prevent severe aGVHD, we studied a series of patients with hematological malignancies undergoing BMT from HLA-identical siblings. Patients conditioned with a standard cyclophosphamide/total body irradiation (TBI) regimen, received a BMT depleted of T cells by elutriation. Fresh donor T cells were transfused on days 30 and 45 post-BMT, to achieve a final T cell dose of 1-5 × 10 7 CD3 + cells/kg, comparable to that normally received in an unmanipulated BMT. The impact of this approach on incidence and severity of acute and chronic GVHD, leukemic relapse and survival is described.
Patients and methods

Patients
Between September 1993 and August 1996, 38 patients with hematological malignancies received T lymphocytedepleted BMT from an HLA-identical sibling. Patients were treated under National Institutes of Health protocols testing T cell-depleted BMT followed by delayed lymphocyte add-back: 93-H-0212 (chronic myeloid leukemia), 94-H-0092 (acute myeloid leukemia and myelodysplastic syndrome), and 94-H-0182 (multiple myeloma), approved by the local Institutional Review Board. Recipient age ranged between 17 and 58 (median 34 years). Nineteen had chronic myeloid leukemia (CML), 13 in chronic phase (CP), three in accelerated phase (AP) and three in blastic phase (BP). Eleven patients had other myeloid malignancies (five myelodysplastic syndrome in transformation (tMDS), five acute myeloid leukemia (AML) (two in second or subsequent remission and three in relapse), and one patient with eosinophilic leukemia). Eight patients had multiple myeloma. Eighteen patients (13 CML CP, three CML AP, two AML in remission) were designated as standard risk for transplant complications and relapse. The remaining 20 patients with more advanced leukemia or multiple myeloma were designated as high risk. Details of diagnosis, previous treatment, and transplant procedure are shown in Table 1 .
Preparative regimen
All patients received 60 mg/kg cyclophosphamide on days −7 and −6 before BMT, followed by fractionated total body irradiation. Patients UPN 1, 2, 3, 5 received a total of 1200 rads in six fractions, together with i.v. antithymocyte globulin (ATG; Upjohn, Kalamazoo, MI, USA) 40 mg/kg × 4 days between days −5 to −2 before BMT. Because this regimen was poorly tolerated, subsequent patients received 60 mg/kg cyclophosphamide on days −7 and −6 before BMT and 1360 rad in eight fractions days −5 to −2 before BMT with no ATG.
Bone marrow transplantation and GVHD prophylaxis
To prevent GVHD, patients received a BMT depleted of T cells by elutriation, carried out as described previously. 16 T lymphocytes (CD3 + cells), were counted in the rotor-off fraction which was supplemented with cells from the 140 and/or 110 fraction, to achieve a T cell dose of about 2 × 10 5 CD3 + cells/kg. As further GVHD prophylaxis, patients received cyclosporine 3 mg/kg i.v., starting day −4 until an oral dose was tolerated. Doses were adjusted to maintain a cyclosporine plasma level between 200-400 g/ml. Cyclosporine was continued to at least day 180 post-BMT, and longer if chronic GVHD developed.
T cell add-back
To reconstitute immune function, patients received fresh mononuclear cells from the donor, obtained by leukapheresis. Two add-back schedules were evaluated: (1) 2 × 10 6 CD3 + cells/kg on day 30 followed by 5 × 10 7 CD3
+ cells/kg on day 45; (2) 1 × 10 7 CD3 + cells/kg on day 30 post-BMT. An exception was made to withhold T cell addback to standard-risk patients (at low risk of relapse) developing grade II or more aGVHD after transplant and any patient being treated for grade II aGVHD. Three patients received add-back at times earlier than scheduled in an attempt to treat cytomegalovirus (CMV) interstitial pneumonia not responding to standard treatment measures.
Post-transplant management
All patients received fluconazole and norfloxacin until day 30 for antifungal and antimicrobial prophylaxis, followed by bactrim weekly from day 30 to 180 as prophylaxis against pneumocystis infection. From May 1995, patients (UPN 24 and subsequent) also received high-dose acyclovir as prophylaxis against CMV and herpes virus reactivation. 17 CMV antigen was monitored weekly until day 100 post-BMT, and ganciclovir with high-dose immunoglobulin was initiated when there was evidence of CMV reactivation. 18 Acute GVHD уgrade II was treated with highdose steroids (0.5-1.0 g/m 2 daily for 3 days) tapered according to response. Patients not responding within 10 days were considered steroid-resistant and received ATG 15 mg/kg daily for at least 10 days. Chronic GVHD was treated with combinations of low-dose prednisolone (10-30 mg daily) and cyclosporine daily or on alternate days, with addition of thalidomide and PUVA treatment for resistant cases.
Hematological recovery and minimal residual disease status was monitored by bone marrow examination on days 21, 100, 6 months, 1 year and yearly thereafter. Karyotype was monitored on marrow samples from informative patients. Minimal residual disease was monitored by a nested PCR analysis of blood samples of CML patients using previously described methods. 19 For PCR analysis, peripheral blood mononuclear cells were obtained by Ficoll separation and frozen in liquid nitrogen. Samples were thawed and run with concurrent positive (K562), negative (HL60), and dilution (K562/HL60) controls as well as diluent controls (no RNA). Serial dilutions of K562 in HL60 RNA showed a lower limit of detection to be 1/10 5 cells. T cell doses were measured by automated cell counting and flow cytometric quantitation of the CD3 + fraction using a FACScan (Becton Dickinson, Mountain View, CA, USA) as described previously. 16 
Statistical analysis
Actuarial probabilities of acute and chronic GVHD, relapse and survival were calculated by the method of Kaplan and Meier. 20 Differences between outcomes were compared using Peto and Peto's modification of Wilcoxon's rank-sum analysis. 21 Fisher's exact test was used to compare differences in the grade of GVHD.
Results
T cell depletion
After elutriation, the final recipient T cell dose was 1. /kg (not shown). CML = chronic myeloid leukemia; CP = chronic phase; AP = accelerated phase; BP = blast phase; MM = multiple myeloma; tMDS = myelodysplasia in transformation; AML = acute myelogenous leukemia; CR = complete remission; rel = relapse; Eo leuk = acute eosinophilic leukemia; aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; l = limited; e = extensive; NE = not evaluable; A/W = alive and well; CMV IP = cytomegalovirus interstitial pneumonia; trf reaction = transfusion reaction; ICH = intracranial hemorrhage; VOD = veno-occlusive disease.
Hematological recovery
All patients engrafted. Two patients who had shown full hematological recovery developed pancytopenia in association with ganciclovir treatment for CMV reactivation.
Outcome
Eighteen patients survive with an actuarial survival of 45.5 ± 8.5% at a median follow-up of 20.5 months. Twenty patients died, five from CMV interstitial pneumonia, four from fungal infections, five from leukemic relapse or progressive myeloma and six from transplant-related causes: two had aGVHD and infection; two had veno-occlusive disease; UPN 13 died from an allergic blood transfusion reaction at another treatment center; UPN 18 had slow platelet engraftment, was refractory to platelet transfusions and died from intracranial hemorrhage ( Table 1) . Current leukemiafree survival was significantly higher in standard-risk compared with high-risk patients (72 ± 9% vs 12 ± 10%, P Ͻ 0.01) (Figure 1 ).
Infectious complications
Overall nine patients died from infectious causes. Reactivation of cytomegalovirus (CMV) was the most common infectious complication occurring in 24 of 32 patients at risk because either recipient or donor was seropositive for CMV. Patients from UPN 1 to 28 received no additional CMV prophylaxis but were treated with ganciclovir if CMV reactivation occurred. 18 Nineteen of 21 patients at risk developed CMV reactivation (95% probability) and five (26%) developed fatal interstitial pneumonia. Subsequent patients at risk for CMV reactivation because of patient or donor seropositivity for CMV received high-dose acyclovir as CMV prophylaxis. 17 Nine of 15 developed CMV reactivation (actuarial probability 68%) but no patient died of complications from CMV. The second most common infection-related mortality was aspergillosis, occurring in four patients, three of whom had multiple myeloma.
Acute GVHD (Figure 2)
A-GVHD following BMT: Five of 38 patients developed grade II aGVHD between day 18 and 31 (actuarial risk 16%), 3/26 in schedule 1 and 2/12 in schedule 2 (before scheduled T cell add-back). Two patients, UPN 1 and 35 had GVHD grade I developing on or before day 30 which progressed by day 31 to grade II aGVHD. Because of its evolution and timing the GVHD was ascribed to the transplant and not the T cell add-back. GVHD mainly affected the skin and responded rapidly to steroid treatment. The actuarial probability of developing aGVHD grade II before the add-back of T cells was 16.5% for all 38 patients (16% for schedule 1 and 18% for schedule 2). aGVHD after T cell add-back, schedule 1: Of 26 patients, six died shortly after day 30 and were not evaluable for GVHD from T cell add-back. (This included three patients who received earlier T cell add-back and died of CMV interstitial pneumonia.) According to protocol, T cell addback was delayed or withheld in three patients developing уgrade II GVHD: UPN 1 had GVHD grade I at the time of add-back on day 30, but progressed to GVHD grade II within 24 h. This standard-risk patient was therefore not given the day 45 add-back. UPN 13 (standard risk), developed grade II GVHD after BMT and was not given further T cells. UPN 32 (high risk), was being treated for GHVD grade II on day 30 after BMT and received only the day 45 T cell add-back. Of the remaining 17 patients receiving the planned T cell add-back, three developed aGVHD (two grade II and one grade III) between day 55 and 137 post-BMT. Of note, no patient developed aGVHD before day 55, suggesting that GVHD followed the day 45, not the day 30 lymphocyte add-back. GVHD in all three patients responded to high-dose steroid treatment. Two became long-term survivors and one died from fungal infection. The actuarial risk of aGVHD уgrade II for schedule 1 was 15.5% following add-back and 31.5% overall.
aGVHD after T cell add-back, schedule 2: Two of 12 patients died too early to receive T cell add-back. Eight of 10 patients given the planned add-back developed aGVHD grade II-IV between day 44-107 post-BMT. The overall actuarial risk of aGVHD уgrade II in schedule 2 was 100%.
The severity of aGVHD in each group is compared in + cells/kg day +30). The probability of уII aGVHD before T cell add-back on day 30 was 15.5% for schedule 1 vs 16.5% for schedule 2. Table 2 . There was no significant difference in the proportion of grade 0-I vs III-IV GVHD following the transplant or after schedule 1 T cell add-back. In contrast GVHD severity following add-back in schedule 2 was significantly more than in schedule 1 (P = 0.001) or after transplant (P = 0.0003). In schedule 2, 50% developed grade II and 30% grade III-IV aGVHD. Two patients died from grade IV aGVHD. In summary, the transfusion of 2 × 10 6 cells on day 30 followed by 5 × 10 7 T cells on day 45 resulted in a low risk of aGVHD, whereas add-back of 10 7 /kg donor lymphocytes on day 30 was associated with a high risk of severe aGVHD. The aGVHD risk from a median T cell dose of 2 × 10 5 /kg at the time of transplant was comparable to the risk following the add-back of more than 2 logs greater T cell dose in schedule 1. Table 2 GVHD severity after T cell-depleted BMT and after add-back of T cells in evaluable patients 
Chronic GVHD
Of 24 evaluable patients surviving more than 100 days post-BMT, 10 (46%) developed chronic GVHD, eight (36%) limited and two (8%) extensive. Eight of 17 patients in schedule 1, and two of seven in schedule 2, developed chronic GHVD. Limited chronic GVHD was well controlled with only five patients still requiring treatment. Both patients with extensive chronic GVHD require continuing treatment.
Relapse
In the 18 standard-risk patients, four relapses occurred (actuarial risk 29 ± 13%). Three achieved a second molecular remission: UPN 26 (CML-AP) and UPN 21 (CML-CP) had a karyotypic relapse at 6 and 12 months, responded to cyclosporine withdrawal and became PCR-negative for BCR-ABL; UPN 19 (CML-CP) had a hematological relapse, responded to donor lymphocytes and interferon and became PCR-negative for BCR-ABL. UPN 25 (CML-AP) had a hematological relapse and achieved a hematological remission after a second transplant. In the 20 high-risk patients, five relapsed or had continuing disease progression (UPN 30) (actuarial risk 69 ± 23%). There were no responses to treatment with chemotherapy or donor lymphocytes and all died of progressive disease. Relapse probability for standard-and high-risk patients is shown in Figure 3 . The difference in relapse risk between the two groups was not significant (P = 0.08).
Minimal residual disease in CML
Twelve patients with CML in CP or AP surviving more than 100 days were serially evaluated by PCR for the BCR-ABL message in blood or marrow cells. At day 100, all but UPN 13 had received T cell add-back and were Ph+ negative by karyotype of bone marrow, but 4/12 were positive by PCR. They subsequently became negative, two spontaneously and two after stopping cyclosporine. At 6 months, 3/11 patients became positive by PCR or karyotype. UPN 19 subsequently developed hematological relapse, UPN 1 and 38 became negative spontaneously. Apart from UPN 25, all surviving patients were negative by PCR at the last evaluation ( Figure 4 ). 
Discussion
One of the major limitations of allogeneic BMT as a treatment for hematological malignancies is the unregulated immune recovery after BMT, which on the one hand confers an important GVL effect and on the other, causes morbidity and mortality from GVHD. 4 In order to control donor immune reconstitution post-transplant by reducing GVHD while conserving useful donor immune function against leukemia and infections, we studied the effect of timing of infusion of donor lymphocytes in the context of a T celldepleted BMT. Recent evidence implicates a preparative regimen-related 'cytokine storm' in the pathogenesis of aGVHD following BMT. 22 By delaying the addition of donor lymphocytes following a T cell-depleted transplant, it might therefore be possible not only to delay, but also circumvent, aGVHD. An earlier study by Naparstek et al. 13 explored the add-back of logarithmically increasing doses of donor lymphocytes after BMT. This study demonstrated a GVL effect from relatively small lymphocyte doses, but with a high incidence of GVHD in the absence of cyclosporine prophylaxis. An alternative strategy, which might have the same GVL effect with less GVHD, would be to addback higher doses of lymphocytes and use cyclosporine. In this study we therefore evaluated add-back of up to 5 × 10 7 donor T cells/kg between 30-45 days after BMT.
We found that up to 5 × 10 7 T cells/kg could be transfused 45 days after BMT, with a risk of aGVHD comparable to that induced by 2 × 10 5 T cells/kg at the time of the BMT (15.5% vs 16%). Thus a 2-log increment in dose of added back T cells was achieved for a comparable GHVD risk. However, the timing and dose of the add-back was critical: on day 30, no aGVHD was observed with a dose of 2 × 10 6 CD3 + cells/kg, but 10 7 CD3 + cells/kg resulted in a 100% risk of severe, and in two cases, lethal aGVHD.
The 34% relapse rate we observed in CML CP and AP patients was considerably less than relapse rates seen after T cell-depleted BMT for CML in CP which may be as high as 60%. [1] [2] [3] [4] The analysis of minimal residual disease by karyotype and PCR showed a tendency to early negativity of the BCR-ABL message in our patients, further suggesting that delayed T cell add-back conserved a GVL effect in CML patients. Since there was no significant reduction in the incidence of chronic GVHD compared with T cell-replete BMT, it is possible that the GVL effect was conserved by the development of chronic GVHD. 2 In choosing the dose and timing of T cell add-back, we attempted to strike a balance between the advantage to immune reconstitution and the GVL effect of early addback and the reduced GVHD risk observed with lower doses of T cells given later. 15 Early add-back would particularly favor a GVL effect in patients at high risk, who relapse in the first few months after BMT. Conversely, in patients with CML in chronic phase, it would be possible to delay add-back without risking relapse in the first 3 months. While the delayed T cell add-back strategy appeared to restore a GVL effect, the antileukemic effect did not surpass the effect achievable with T cell replete transplants. Techniques to selectively add-back T cells with specific anti-leukemia reactivity are required to overcome these shortcomings. 23 The 72% and 12% current disease-free survival for standard-risk and advanced disease patients respectively is comparable to that currently achieved in T cell-replete transplants in similar patients. [24] [25] [26] [27] [28] [29] [30] However, controlling the timing and severity of GVHD after BMT by delayed T cell add-back, may ultimately contribute to improved transplant outcome. This possibility is realistic because several problems in the protocol, which contributed to transplant-related mortality, have been successfully addressed. First, our data identify suitable doses and timing of T cell add-back for future protocols. Second, CMV pneumonitis has been prevented by high-dose acyclovir prophylaxis in over 50 consecutive patients transplanted after UPN 23. Third, we have improved the method of stem cell collection: the T cell depletion achieved by the elutriation procedure was insufficient to prevent GVHD in every patient and resulted in considerable CD34
+ cell loss. We previously reported that the low CD34 + cell transplant dose contributed to an increased TRM. 16 It has yet to be demonstrated that T cell depletion followed by delayed T cell add-back can improve the outcome after allogeneic marrow stem cell transplantation. To study the approach further, we have now optimized T cell and CD34
+ cell doses by positive selection of CD34 + cells and additional T cell depletion of peripheral blood progenitor cell (PBPC) transplants. A study incorporating these modifications, evaluating T cell-depleted PBPC transplants, followed by delayed T cell add-back is now underway.
